zoladex® la 10.8mg depot soloution for subcutaneous injection
astrazeneca pharmaceuticals (phils.), inc. - goserelin acetate ( equivalent to goserilin base) - depot soloution for subcutaneous injection - 10.8mg
zoladex® la 10.8mg depot soloution for subcutaneous injection
astrazeneca pharmaceuticals (phils.), inc. - goserelin acetate ( equivalent to goserilin base) - depot soloution for subcutaneous injection - 10.8mg
zoladex
astrazeneca uk limited - goserelin acetate - implant - 3.6 base milligrams - goserelin
zoladex la
astrazeneca uk limited - goserelin acetate - implant - 10.8 base milligrams - goserelin
goserelin
teva pharma (new zealand) limited - goserelin acetate 12.5mg equivalent to 10.8 mg goserelin - subcutaneous implant - 10.8 mg - active: goserelin acetate 12.5mg equivalent to 10.8 mg goserelin excipient: poly(lactide) polyglactin - prostate cancer suitable for hormonal manipulation. adjuvant and neoadjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.
goserelin
teva pharma (new zealand) limited - goserelin acetate 4.1mg equivalent to 3.6 mg goserelin - subcutaneous implant - 3.6 mg - active: goserelin acetate 4.1mg equivalent to 3.6 mg goserelin excipient: polyglactin - prostate cancer suitable for hormonal manipulation. adjuvant and neoadjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation
zoladex la 10.8 base milligrams implant
profind wholesale ltd - goserelin acetate - implant - 10.8 base milligrams
zoladex depot injection 3.6 mgsyringe
astrazeneca singapore pte ltd - goserelin acetate eqv peptide - injection - 3.6 mg/syringe - goserelin acetate eqv peptide 3.6 mg/syringe
zolacos cp
astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin; ; bicalutamide 50mg - combination - 10.8mg+50mg pack - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin excipient: polyglactin active: bicalutamide 50mg excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.
zolacos cp
astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin; ; bicalutamide 50mg; - combination - 3.6mg + 50mg pack - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin excipient: polyglactin active: bicalutamide 50mg excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.